Imigran

Sumatriptan, the active ingredient in Imigran, is a selective serotonin 5‑HT1B/1D receptor agonist presented as a 6 mg/0.5 ml subcutaneous injection for rapid onset use. It is indicated for the acute treatment of migraine attacks in adult patients.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU GMP standards and providing full traceability for each batch. The formulation is designed for single‑use administration and is packaged in sterile, tamper‑evident syringes, ensuring safety and convenience for healthcare providers.

Sumatriptan is used in the acute management of migraine, a neurovascular headache disorder.

Migraine attack: provides rapid relief of headache pain and associated symptoms when taken at the onset of an attack.

Sumatriptan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild discomfort at the injection site. - Tingling or flushing: transient sensations of warmth, tingling, or redness. - Nausea or dizziness: mild gastrointestinal upset or light‑headedness. - Fatigue: temporary feeling of tiredness.

Serious or Rare Side Effects: - Chest discomfort or tightness: possible cardiac ischemia. - Severe hypertension or stroke: sudden rise in blood pressure or rare cerebrovascular event. - Allergic reaction or serotonin syndrome: rash, swelling, anaphylaxis, or symptoms of serotonin excess when combined with other serotonergic drugs. - Coronary vasospasm: constriction of coronary arteries leading to chest pain.

When prescribing Sumatriptan, clinicians should observe several precautionary measures to minimize risk.

Contraindicated in patients with known coronary artery disease: avoid use due to risk of vasospasm. Avoid in uncontrolled hypertension: may exacerbate blood pressure. Use with caution in patients with cerebrovascular disorders: monitor for neurological symptoms. Do not combine with MAO inhibitors or other serotonergic agents: risk of serotonin syndrome. Pregnancy and lactation: safety not established; prescribe only if benefit outweighs risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sumatriptan can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may precipitate serotonin syndrome. - SSRIs, SNRIs, or other serotonergic agents: increased risk of serotonin toxicity. - Ergot alkaloids or other triptans: additive vasoconstrictive effects can cause severe cardiovascular events.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase sumatriptan plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy of sumatriptan.